Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D, ASCEND investigators

Open source

DOI: 10.1016/s1474-4422(18)30069-3
Published: 2018 May
Container: The Lancet. Neurology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1474-4422-18-30069-3,
  title = {Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.},
  author = {Kapoor R and Ho PR and Campbell N and Chang I and Deykin A and Forrestal F and Lucas N and Yu B and Arnold DL and Freedman MS and Goldman MD and Hartung HP and Havrdová EK and Jeffery D and Miller A and Sellebjerg F and Cadavid D and Mikol D and Steiner D and ASCEND investigators},
  year = {2018},
  journal = {The Lancet. Neurology},
  doi = {10.1016/s1474-4422(18)30069-3},
  url = {https://doi.org/10.1016/s1474-4422(18)30069-3}
}

RIS

TY  - JOUR
TI  - Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
AU  - Kapoor R
AU  - Ho PR
AU  - Campbell N
AU  - Chang I
AU  - Deykin A
AU  - Forrestal F
AU  - Lucas N
AU  - Yu B
AU  - Arnold DL
AU  - Freedman MS
AU  - Goldman MD
AU  - Hartung HP
AU  - Havrdová EK
AU  - Jeffery D
AU  - Miller A
AU  - Sellebjerg F
AU  - Cadavid D
AU  - Mikol D
AU  - Steiner D
AU  - ASCEND investigators
PY  - 2018
JO  - The Lancet. Neurology
DO  - 10.1016/s1474-4422(18)30069-3
UR  - https://doi.org/10.1016/s1474-4422(18)30069-3
ER  -

APA

R, K., PR, H., N, C., I, C., A, D., F, F., N, L., B, Y., DL, A., MS, F., MD, G., HP, H., EK, H., D, J., A, M., F, S., D, C., D, M., D, S., & investigators, A. (2018). Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(18)30069-3

Source records

pubmed · retrieved 2026-09-26T11:47:52.511Z
europe-pmc · retrieved 2026-09-26T11:47:52.509Z
hal · retrieved 2026-09-26T11:47:52.533Z